Skip to main content

Tali M. Tuchin


[email protected]



Tali holds 20 years of significant experience handling complex business and technology transactions to help clients in sectors such as biotechnology, pharmaceuticals, diagnostics, medical devices, health care, energy, and technology negotiate deals that advance their commercial interests while minimizing their risk.

Her clients work on the cutting edge technology, including RNA medicines, antibody and protein therapeutics, vaccines, reproductive healthcare products, oncology platforms, pain relief, brain health, orphan drugs, research reagents, and in vitro and clinical diagnostics.

Tali works closely with clients ranging from start-ups to large public companies to structure and negotiate mission-critical transactions. She provides strategic counsel on patent licenses and assignments, research and development agreements with complex intellectual property provisions, collaboration and option agreements, and high-value software licenses — working to keep her clients’ critical deals on track while ensuring compliance with industry regulations and maximizing business value.

Leveraging her prior experience as in-house corporate counsel for a large, publicly traded biotech company, Tali is a trusted business advisor who understands and accommodates the variables that can impact a complex deal. Companies count on her comprehensive transaction experience and knowledgeable advice to help them manage investor needs and expectations, contain legal costs, accommodate various internal client functions and business units, and overcome negotiation impasses. Her clients benefit from her many years of practice and the creative thinking she brings to problem solving.

Tali also handles transactions for a wide range of routine business matters, including material transfer agreements, clinical supply and research agreements, manufacturing and supply agreements and services agreements, and helps clients manage and review day-to-day, high-volume work, such as confidentiality agreements, customer agreements, and terms and conditions.


  • Arcturus Therapeutics (Nasdaq:ARCT), a leading clinical-stage messenger RNA medicines company, in connection with its partnership agreement with CSL Seqirus for a global vaccine leader, for the research, development, manufacture, and global commercialization of vaccines
  • Daré Bioscience in connection with its partnership agreement with Oragonon a global women’s healthcare company
  • Caladrius Biosciences (Nasdaq:CLBS), a biopharmaceutical company engaged in regenerative medicine and stem cell research, in connection with its merger with Cend Therapeutics – the combined company will operate under the name Lisata Therapeutics (Nasdaq:LSTA)
  • Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a biotherapeutics company, in a license agreement with Baylor BioSciences, a life sciences company
  • Immusoft Corporation in its first Big Pharma collaboration in a deal with Takeda valued at $900M
  • Walk Vascular, LLC, a commercial-stage medical device company with a minimally invasive mechanical aspiration thrombectomy system designed to remove peripheral blood clots, in connection with its sale to Abbott (NYSE:ABT)
  • BlinkBio in out-licensing its patent rights to OS Therapies, a late-stage clinical research biotechnology company focused on Osteosarcoma and other solid tumors
  • BlinkBio in out-licensing its patent rights to ADC Therapeutics, a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (ADCs) for patients with hematological malignancies and solid tumors
  • Nuvve Corporation (Nasdaq:NVVE) with respect to its electric school bus and fleet vehicle  electrification-as-a-service joint venture with Stonepeak Infrastructure Partners providing up to $750M in financing
Read less


Amid a tough equity market and an ebb in investment in the biotech sector, early- or growth-stage companies focused on drug discovery and development may want to spend some time exploring strategic partnerships with other businesses at the 2023 BIO International Convention.

Read more
Read less

News & Press

Press Release Thumbnail

Mintz is pleased to announce that 120 firm attorneys have been recognized as leaders by Best Lawyers® in the 2024 edition of The Best Lawyers in America©.

Press Release Thumbnail

Best Lawyers® recognized 108 firm attorneys in the 2023 edition of The Best Lawyers in America©. Notably, two Mintz attorneys – Poonam Patidar and Scott M. Stanton – received 2023 “Lawyer of the Year” awards, and 28 firm attorneys were included in the inaugural edition of Best Lawyers: Ones to Watch.

Mintz is pleased to announce Tali M. Tuchin has been named a finalist for the 2018 Athena Pinnacle Awards. Ms. Tuchin, Special Counsel in the firm’s San Diego office, has been recognized in Athena’s “Individual in Services” category.
Read less

Events & Speaking


Living Heart Healthy & Stress-Free

Willis Towers Watson, San Diego, CA

Read less

Recognition & Awards

  • Recognized by Athena - Pinnacle Award Finalist - Individual in Services (2018)

  • Best Lawyers in America: IT/Outsourcing Law (2023 – 2024)

Read less


  • Member, Athena Forum for Executive Women (FEW) group (2010-present)
  • Member, Lawyers Club of San Diego
  • Volunteer, Women in Bio, San Diego Chapter (2022-present)
Read less